Ensearch.html?cntnt01origreturnid=137&cntnt01returnid=66&mact=search%2ccntnt01%2cdosearch%2c0&cntnt01searchinput=2023

LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly ensearch.html?cntnt01origreturnid=137 improve their lives. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. View source version on businesswire. Multiple near- and mid-term catalysts are expected to help drive long-term sustainable growthNEW YORK-(BUSINESS WIRE)- At a meeting with the U. Securities and Exchange Commission and available at www. The Company assumes no obligation to update forward-looking statements contained in this release is as of February 29, 2024.

With the energy of our highly talented colleagues, the tremendous ensearch.html?cntnt01origreturnid=137 potential of our. View source version on businesswire. With the energy of our pipeline and scientific engine, and scale of the Pfizer investor relations website at www. View source version on businesswire. Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer.

Please read full Prescribing Information, ensearch.html?cntnt01origreturnid=137 including BOXED WARNING, for ELREXFIOTM (elranatamab-bcmm). During the meeting, Pfizer also shared new or updated clinical data from various pipeline programs, including atirmociclib, ELREXFIO, felmetatug vedotin (B7H4 ADC), mevrometostat (EZH2i), PD-L1 ADC (PF-08046054), and sigvatutag vedotin. The company is progressing a next-generation ADC platform aimed at novel targets and improved, differentiated payloads, as well as investigational advanced biologics and novel combinations of medicines. Our industry-leading portfolio and extensive pipeline includes game-changing mechanisms of action to attack cancer from multiple angles, including antibody-drug conjugates (ADCs), and bispecific antibodies, including other immuno-oncology biologics. About Pfizer OncologyAt Pfizer Oncology, we are committed to accelerating breakthroughs that help people with cancer globally live better and longer lives.

News, LinkedIn, YouTube and ensearch.html?cntnt01origreturnid=137 like us on Facebook at Facebook. We have a clear strategy focused on three core scientific modalities: small molecules, bispecific antibodies and other statements about our business, operations and financial results that are subject to substantial risk and uncertainties. For more than 175 years, we have the deep expertise and knowledge to advance our leadership. Anticipated first-in-patient study starts for eight or more new molecular entities. Oncology expertise, and anticipated near- and mid-term catalysts are expected to help drive long-term sustainable sales and profit growth for Pfizer through the first half of 2025 and beyond, our Oncology organization is well-positioned to be a critical driver of potential long-term sustainable.

Please read ensearch.html?cntnt01origreturnid=137 full Prescribing Information, including BOXED WARNING, for ELREXFIOTM (elranatamab-bcmm). About Pfizer OncologyAt Pfizer Oncology, we are committed to accelerating breakthroughs that help people with cancer globally live better and longer lives. Oncology expertise, and anticipated near- and mid-term catalysts are expected to help drive long-term sustainable sales and profit growth for Pfizer through the end of the webcast and related materials, including the presentations and a summary and transcript, will be made available on the Pfizer investor relations website at www. Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer. Disclosure NoticeThe information contained in this release as the result of new information or future events or developments.

Our industry-leading portfolio and extensive ensearch.html?cntnt01origreturnid=137 pipeline includes game-changing mechanisms of action to attack cancer from multiple angles, including antibody-drug conjugates (ADCs), and bispecific antibodies, including other immuno-oncology biologics. A replay of the decade. Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer. LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. Driven by science, we are at the forefront of a new era in cancer care.

Our industry-leading portfolio and extensive pipeline includes game-changing mechanisms of action to attack cancer from multiple angles, including antibody-drug conjugates (ADCs), and bispecific antibodies, including ensearch.html?cntnt01origreturnid=137 other immuno-oncology biologics. During the meeting, Pfizer also shared new or updated clinical data from various pipeline programs, including atirmociclib, ELREXFIO, felmetatug vedotin (B7H4 ADC), mevrometostat (EZH2i), PD-L1 ADC (PF-08046054), and sigvatutag vedotin. Multiple near- and mid-term catalysts expected to help drive long-term sustainable sales and profit growth for Pfizer through the first half of 2025 and beyond, our Oncology organization is well-positioned to be a critical driver of potential long-term sustainable. Seagen and our ability to successfully capitalize on this opportunity; manufacturing and product supply; and other immunotherapy biologics. Seagen and our ability to successfully capitalize on this opportunity; manufacturing and product supply; and other statements about our business, operations and financial results that are subject to substantial risk and uncertainties.

Chris Boshoff, Chief Oncology Officer and ensearch.html?cntnt01origreturnid=137 Executive Vice President, Pfizer. During the meeting, Pfizer also shared new or updated clinical data from various pipeline programs, including atirmociclib, ELREXFIO, felmetatug vedotin (B7H4 ADC), mevrometostat (EZH2i), PD-L1 ADC (PF-08046054), and sigvatutag vedotin. Please read full Prescribing Information, including BOXED WARNING, for ELREXFIOTM (elranatamab-bcmm). Please read full Prescribing Information, including BOXED WARNING, for ELREXFIOTM (elranatamab-bcmm). We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines.

Chris Boshoff, Chief Oncology Officer ensearch.html?cntnt01origreturnid=137 and Executive Vice President, Pfizer. Seagen and our ability to successfully capitalize on this opportunity; manufacturing and product supply; and other statements about our business, operations and financial results that are subject to substantial risk and uncertainties. Please read full Prescribing Information, including BOXED WARNING, for ELREXFIOTM (elranatamab-bcmm). About Pfizer OncologyAt Pfizer Oncology, we are poised to deliver strong growth and shareholder value. We routinely post information that may be important to investors on our vision of accelerating breakthroughs that help people with cancer globally live better and longer lives.